文献速递外周动脉疾病

定向斑块旋切联合抗再狭窄治疗与PTA/Supera支架治疗腘动脉病变的比较:倾向性匹配分析

Directional Atherectomy With Antirestenotic Therapy Versus PTA/Supera Stenting for Popliteal Artery Lesions: A Propensity-Matched Analysis.
PubMed 文献 · J Endovasc Ther · 2023-09-20

本研究回顾性比较定向斑块旋切联合抗再狭窄治疗(DAART)与经皮腔内血管成形术(PTA)/Supera支架植入治疗腘动脉病变的结局。倾向性匹配后53对患者短期和1年结局均无显著差异,包括一期通畅率(73.6% vs 77.4%,p=0.233)。

要点

  • 倾向性匹配后,DAART组与PTA/Supera支架组的技术成功率分别为96.2%和98.1%,无显著差异(p=0.232)。
  • 1年一期通畅率DAART组73.6% vs PTA/Supera支架组77.4%,无显著差异(p=0.233)。
  • DAART技术被呈现为「leave nothing behind」策略,其一年临床结局与PTA/Supera支架相似。

核心结论

  • DAART技术或PTA/Supera支架治疗腘动脉粥样硬化病变的12个月结果无差异,与患者和斑块特征无关。

研究设计与样本

  • 回顾性数据库识别2016年1月至2021年12月期间接受DAART或PTA/Supera支架治疗的143例孤立性腘动脉粥样硬化病变连续患者(平均年龄75.0±12.2岁,72%男性)。
  • 采用倾向性评分匹配的病例对照分析平衡DAART组与PTA/Supera支架组之间的协变量。

主要发现

  • 共51例(35.7%)表现为严重跛行,92例(64.3%)为严重肢体缺血。
  • PTA/Supera支架组有更长治疗病变的趋势(90.4±81 vs 72.5±5.3 mm,p=0.089)和更多慢性完全闭塞(60.5% vs 46.8%,p=0.058),但未达统计学显著。
  • 中重度钙化存在于大多数病变中(DAART组75.8%,PTA/Supera支架组80.2%,总队列78.3%)。
  • 53对匹配患者中,短期结局无显著差异:技术成功率(96.2% vs 98.1%,p=0.232)、手术成功率(88.7% vs 90.1%,p=0.251)、远端栓塞(1.9% vs 1.9%,p=0.178)、夹层(5.7% vs 1.9%,p=0.268)、穿孔(3.8% vs 5.6%,p=0.163)、住院时间(1.2±0.1 vs 1.0±0.1,p=0.325)、30天小截肢率(28.3% vs 32.1%,p=0.264)或大截肢率(7.5% vs 3.8%,p=0.107)、30天死亡率(1.9% vs 1.9%,p=0.173)。
  • 1年时,DAART组与PTA/Supera支架组的一期通畅率(73.6% vs 77.4%,p=0.233)、一期辅助通畅率(81.3% vs 84.9%,p=0.167)、二期通畅率(86.8% vs 92.5%,p=0.094)、同侧小截肢率(35.8% vs 39.6%,p=0.472)或大截肢率(9.4% vs 7.5%,p=0.186)、踝肱指数改善(0.32±0.12 vs 0.37±0.37,p=0.401)或死亡率(5.7% vs 5.7%,p=0.121)均无差异。

临床怎么用

  • 作者认为,DAART技术可作为治疗腘动脉粥样硬化疾病的一种「leave nothing behind」策略,其一年临床结局与PTA/Supera支架相似。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: This study examines the use and impact of directional atherectomy with antirestenotic therapy (DAART) versus angioplasty plus Supera stent implantation on the outcomes during endovascular treatment of popliteal lesions in clinical practice. METHODS: Overall 143 consecutive patients (mean age 75.0±12.2 years, 72% male), with isolated atherosclerotic disease of the popliteal artery who underwent endovascular treatment using DAART therapy or percutaneous transluminal angioplasty (PTA)/Supera stenting of the popliteal artery between January 2016 and December 2021 were identified from a retrospectively database. Patient and plaque characteristics were collected. A propensity-score matched, case-control analysis was conducted to balance covariates between the group of patients who underwent DAART and the one treated by PTA/Supera stenting. RESULTS: A total of 51 patients (35.7%) showed severe claudication and 92 (64.3%) critical limb ischemia. There was a trend toward longer treated lesions (90.4±81 vs 72.5±5.3 mm, p=0.089) and more chronic total occlusions (60.5% vs 46.8%, p=0.058) in the PTA/Supera stenting group, although not reaching statistically significance. Moderate-to-severe calcification was present in most lesions treated (75.8% of DAART group, 80.2% of PTA/Supera stenting group, and 78.3% of total cohort). Among the 53 case-matched pairs of patients treated with DAART or PTA/Supera stenting, there were no significant differences in short-term outcomes, including rate of technical success (96.2% vs 98.1%, p=0.232), procedural success (88.7% vs 90.1%, p=0.251), distal embolization (1.9% vs 1.9%, p=0.178), dissection (5.7% vs 1.9%, p=0.268), perforation (3.8% vs 5.6%, p=0.163), hospital discharge (1.2±0.1 vs 1.0±0.1, p=0.325), 30 day minor (28.3% vs 32.1%, p=0.264) or major amputation rates (7.5% vs 3.8%, p=0.107), and 30 day mortality (1.9% vs 1.9%, p=0.173). At 1 year, there was no difference in primary patency (73.6% vs 77.4%, p=0.233), primary assisted patency (81.3% vs 84.9%, p=0.167), secondary patency (86.8% vs 92.5%, p=0.094), ipsilateral minor (35.8% vs 39.6%, p=0.472) or major amputation (9.4% vs 7.5%, p=0.186), ankle brachial index improvement (0.32±0.12 vs 0.37±0.37, p=0.401), or mortality (5.7% vs 5.7%, p=0.121) rate between patients who underwent DAART or PTA/Supera stenting for popliteal lesions. CONCLUSION: Twelve-month results following DAART technique or PTA/Supera stenting of atherosclerotic lesions of the popliteal artery are not different, regardless of patient and plaque characteristics.Clinical ImpactThe DAART technique for the treatment of popliteal artery atherosclerotic disease is presented as a "leave nothing behind" strategy with on-year clinical outcomes similar to ATP/Supera stenting.

来源:J Endovasc Ther,查看原文。版权归原作者所有。

引用

  1. San Norberto EM, Revilla Á, Brizuela JA, et al. Directional Atherectomy With Antirestenotic Therapy Versus PTA/Supera Stenting for Popliteal Artery Lesions: A Propensity-Matched Analysis. J Endovasc Ther. 2023. PMID: 37728000. doi:10.1177/15266028231199923

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。